Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Yutaka Nakashima, Andrew Plump, Elaine W. Raines et al. · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · 1994 · 1.7K citations

Veterinary Medicine, Cardiology, Pathobiology +17

SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor

M Rinaldi-Carmona, Francis Barth, Jean‐Marie Derocq et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 705 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Anne‐Marie Malfait, Ruth Gallily, Percy F. Sumariwalla et al. · Proceedings of the National Academy of Sciences · 2000 · 663 citations

Medicine, Pharmacology, Pharmacotherapy +15

Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression.

R L Reddick, S H Zhang, Nobuo Maeda · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · 1994 · 635 citations · Full text

Veterinary Medicine, Cardiology, Aging +16

Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor

Nancy E. Buckley, Kathleen L. McCoy, Éva Mezey et al. · European Journal of Pharmacology · 2000 · 542 citations

Life Sciences, Immunology, Pharmacology +6